Metabolic Signatures and Biomarkers in Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Metabolomics
Eligibility Criteria
Inclusion Criteria:
- Age 18-60 years
- Diagnosis of schizophrenia
- Actively psychotic
- No more than a single dose of antipsychotic in the preceding 2 weeks
Exclusion Criteria:
- Mental retardation, epilepsy or history of head trauma
- Substance use disorder that explains the majority of the psychopathology
- Pregnant or lactating females
Sites / Locations
- John Umstead Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Other
Aripiprazole for 4 weeks
Risperidone for 4 weeks
Healthy volunteers
Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.